AlphAIalphai — Financial news for AI agents
news.alphastreet.comAUG 63 min read$SRRK

Scholar Rock Holding Posts Narrower Than Expected Q2 2026 Loss

Scholar Rock Holding (NASDAQ: SRRK) reported a Q2 2026 loss of $0.84 per share, slightly better than the $0.86 expected, with no revenue as it remains pre-commercial. Net loss was $109.9 million. The loss narrowed from $0.98 in Q2 2025. Shares were largely unchanged; analysts show 14 buys, 1 hold, 0 sells.

Original reporting
news.alphastreet.com
Published Aug 6, 2026, 3:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Scholar Rock Holding Posts Narrower Than Expected Q2 2026 Loss — source image
Source · news.alphastreet.com
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The narrower-than-expected loss is a supportive datapoint, but the lack of revenue and muted share reaction suggest limited incremental information for valuation versus upcoming clinical milestones.

02

Market read

Traders likely treat this as an in-line earnings datapoint, with attention shifting to future clinical and regulatory catalysts and cash runway.

03

What to watch

The article does not disclose cash balance, guidance, or specific trial readouts; traders may need those details to assess dilution risk and catalyst timing.

Relevance 5/10Novelty 4/10Timing: reported Q2 2026 results on 2026-08-06

Background

Scholar Rock is described as a clinical-stage, pre-commercial biotech with no revenue and ongoing R&D investment.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock reported a Q2 2026 loss of $0.84 per share, slightly better than the $0.86 expected, with no revenue due to pre-commercial status.

Expected impact

Low incremental impact; shares were described as largely unchanged after the report.

Evidence & confidence

The article provides a small EPS loss beat and notes muted stock reaction, with no new clinical, regulatory, or financing catalyst disclosed.

Market effects

Sector

Reinforces that development-stage biotech investors are still trading primarily on clinical progress and runway rather than quarterly revenue.

Regional

No specific regional spillover mentioned.

Global

No global macro or cross-border deal/regulatory linkage mentioned.

Counterpoint

What could challenge this read

A modest loss beat may mask underlying cash burn pressure, so the market’s lack of reaction could reflect skepticism about runway or trial timelines not detailed here.

Key entities

  • company
    Scholar Rock Holding Corporation

    NASDAQ-listed clinical-stage biotech reporting Q2 2026 results with a narrower-than-expected per-share loss and no revenue.

Read at source← All news

Related articles

AUG 6
$SRRKMed

Scholar Rock Holding Corp (SRRK): Results of Operations and Financial Condition

Scholar Rock Holding Corp (SRRK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srrk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-fi

SEC EDGAR 8-K6 min
AUG 8
$RIVNMed

What Rivian And Lucid's Latest Earnings Say About The EV Startup Race

The article compares Rivian and Lucid after their 2021 IPOs, focusing on recent earnings. Lucid reported $405 million revenue in the quarter, with net loss widening to over $1 billion, and announced an “operational reset” tied to $1.4 billion cash savings in 2026, plus $3 billion liquidity. Rivian reported $1.66 billion revenue last quarter and raised 2026 delivery guidance to 65,000-70,000 vehicles.

insideevs.com6 min
AUG 8
$LNGMedAI 8/10

Cheniere Energy Q2 Earnings Call Highlights

Cheniere Energy’s Q2 earnings call said updated guidance includes about $300 million from additional expected production, with Corpus Christi Stage 3 over 98% complete and Train 7 entering commissioning. The company signed a roughly $4.7 billion EPC contract for Sabine Pass Phase I, targeting FID in early next year. Cheniere repurchased 2.2 million shares for $550 million and declared a $0.555 dividend.

yahoo.com6 min
AUG 8
$INBKMedAI 8/10

First Internet Bancorp (INBK) Q2 2026 Earnings Call Transcript

First Internet Bancorp (INBK) reported Q2 2026 revenue of $41.1 million, up 23%, and non-GAAP diluted EPS of $0.27 versus $0.02 a year earlier. Net interest margin (FTE) rose to 2.47%. Credit costs eased, but net charge-offs were $16.9 million. Full-year 2026 EPS guidance is $2.35 to $2.45.

fool.com7 min
AUG 8
$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

yahoo.com5 min
AUG 8
$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

yahoo.com6 min